Site Search
Displaying results 191 - 200 of 573
Resource | Publications,
According to the WHO, about 2.3 million people are co-infected with HIV and the hepatitis C virus (HCV). Moreover, there were an estimated 1.75 million new hepatitis C virus (HCV) infections worldwide in 2015. HCV usually presents only mild symptoms, if any, until it is at an advanced stage, thereby making it difficult to recognize the disease early.
Resource | Publications,
The purpose of this study was to document why significant numbers of men who have sex with men based in Metropolitan Manila (also known as Greater Manila, Metro Manila and Manila) currently do not access HIV services at different levels of the HIV treatment cascade.
Qualitative interviews were conducted with 48 men who have sex with men from four cities in Metropolitan Manila to explore barriers they faced at four levels of the HIV service cascade: HIV testing; the follow-up of a reactive HIV test; enrolling on antiretroviral treatment (ART); and adhering to ART.
The reasons for all of these barriers are diverse. Some are at the social level in terms of stigma and discrimination, or economic hardship. Some are internal, based on the attitudes, beliefs or behaviour of the men. Other barriers are institutional, at the policy level or in the health care system.
Resource | Tools,
In the 37th meeting of the Community Forum on AIDS (CFA), the request was made that ACA provide the reasoning for not adopting suggestions (if any) raised by stakeholders during the strategy formulation. In the 92nd ACA meeting, members agreed to address those suggestions that were most controversial, with a view to helping stakeholders and relevant communities understand the rationales behind the new set of Strategies, and also draw support from society at large.
Accordingly, this document lays out the rationales during the process of formulating the Strategies for 2017-2021, including the key factors considered, the guiding principles, the views collected during stakeholder and public consultation, and the deliberations involved in some specific issues.
Resource | Fact Sheets,
A preventive HIV vaccine would teach the immune system to create responses that prevent the virus from establishing infection in the body. No licensed preventive HIV vaccine exists at present.
A therapeutic HIV vaccine would improve the body’s immune response to HIV in people living with HIV and thereby reduce their risk of getting sick and, ideally, also reduce their reliance on antiretroviral treatment. Therapeutic vaccine research may provide important clues to the ongoing search for a cure for HIV. No proven therapeutic HIV vaccine exists at present.
This factsheet focuses on research into preventive vaccines for use by HIV-negative people.
Resource | Publications,
During 2016, a total of 249 HIV cases were newly reported in Sri Lanka. This is the highest number reported in a year since the identification of the first HIV infected Sri Lankan in 1987 and this amounts to about 21 persons newly reported with HIV for a month. However, the reported numbers represent only a fraction of HIV infected people in the country as many infected persons may perhaps not be aware of their HIV status and in addition, stigma and discrimination towards HIV hinder seeking HIV testing services.
Resource | Publications,
These are hectic times. There is more information coming at all of us than at any time in human history. And in many parts of the world, that information raises cause for alarm or concern. There are multiple top-priority issues. Many things need attention right now.
How, then, do we advocate for an HIV vaccine, which will not be available until into the 2020s, at the earliest? We advance a near-, mid- and long-term agenda with passion and precision. Moreover, advocates—the “we” invoked throughout this piece—can do this work with more confidence than ever. The history of the response to many other epidemics tells us that an effective preventive vaccine is essential. An epidemic can be controlled with treatment and other prevention—just as HIV is coming under control today. But a sustained end has almost always depended on a vaccine. This year on HIV Vaccine Awareness Day, our core message is simple: No end without a vaccine; no vaccine without funding.
Resource | Laws and Policies,
This is an Act to provide for the prevention and control of the spread of Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome and for the protection of human rights of persons affected by the said virus and syndrome and for matters connected therewith or incidental thereto.
Resource | Publications,
This International Drug Policy Consortium (IDPC) briefing paper provides an analysis of the current drug treatment system in China and offers recommendations for ensuring its effectiveness.
Resource | Publications,
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R and D) of new and effective antibiotic treatments. To date, the selection of pathogens for R and D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.
Resource | Publications,
This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services.